Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir safety in advanced HIV disease with cytomegalovirus viraemia
PACTR202507522416399Phase 2Not yet recruiting
- Sponsor
- Wits Health Consortium
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in cytomegalovirus disease (CMV) and human immunodeficiency virus infection (HIV) comparing Valganciclovir with Matching placebo (2 arms). Primary endpoint: Adverse events of special interest plus re-hospitalisation or death. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus disease (CMV)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202507522416399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202507522416399.